We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Information and sources of further guidance relating to the current shortage of products used in the treatment of some bladder cancers
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 17 July 2024, approved the medicine vibegron (Obgemsa) to treat the symptoms of overactive bladder (OAB) syndrome in adults. Symptoms may include a sudden need to empty the bladder...
This document contains a synopsis of causation occurring in cancer of the bladder.
This is the council’s note about bladder cancer and mineral oils.
A review of the risk of bladder cancer in hairdressers, barbers and textile workers.
This is the council’s note about the risk of bladder cancer in pre-bake aluminium smelters.
This is the council's note about lung and bladder cancer and diesel exhaust emissions.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).